News

Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures. Financing will advance a potential once-daily oral treatment designed to restore blood vessel stability in HHT, a serious inherited bleeding disorder with no approved therapies. periSCOPE platform supports pipeline expansion across vascular diseases

HepaRegeniX to seamlessly advance darizmetinib’s clinical development to Phase 2a following completion of the Phase 1b in 2026 Tuebingen, Germany, September 22, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today announced that the first patient undergoing major liver resection due to liver metastases originating from colorectal cancer has completed

U.S. FDA Orphan Drug Designation underscores darizmetinib’s potential to address a significant unmet need following liver resection Tuebingen, Germany, August 26, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to darizmetinib (formerly HRX215) for the

The collaboration will focus on non-adherence, missed appointments, and clinical trial retention. BRUSSELS, Belgium – June 23, 2026 – Cognivia announced a collaboration with Mayo Clinic aimed at advancing behavioral intelligence across clinical research and clinical care. Building on Cognivia’s behavioral intelligence capabilities and Mayo Clinic’s expertise in patient care and shared decisionmaking, the collaboration will initially focus on three important

Tuebingen, Germany, February 11, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinicalstage biotech company advancing novel therapies for acute and chronic liver diseases, today announced the completion of the Phase Ib minor resection study of HRX-215. Five patients in the clinical trial were treated with HRX-215 for a period of 28 days after a minor liver resection (≤ 30%) due to liver

And continued progress of its alpestria-1 clinical phase 2 study in alport syndrome patient Vonafexor reversed a historical mean eGFR decline of -6.4 mL/min/1.73 m²/yr to a mean functional gain on-treatment of +4.8 mL/min/1.73 m²/yr from baseline 73% of patients maintained albuminuria reduction three months after treatment cessation consistent with a true disease-modifying effect Company plans to advance vonafexor to